BioCardia, Inc. Price & Performance (BCDAW)

BioCardia’s Q1 2025 report highlighted significant clinical advancements, notably in its CardiAMP HF trial, which showed improved survival and reduced cardiac events for heart failure patients. Despite a widened net loss to $2.7 million, investor confidence surged, with shares rising 6.5% in aftermarket trading, reflecting optimism in the company’s expanding pipeline.123

Recent insider purchases totaling nearly $450,000 by BioCardia’s chairman and a director signal strong internal confidence, as the company’s CardiAMP HF therapy shows a 47% reduction in heart-related deaths in Phase 3 trials. These developments support BioCardia’s belief in the therapy’s potential to transform heart failure treatment and reduce care costs.45

BioCardia’s stock has received a technical upgrade following a 1.09% price increase and heightened trading volume. Buy signals from both short- and long-term moving averages suggest a positive short-term trend, with forecasts indicating a potential 2.26% rise over the next three months despite the stock’s high volatility.3